Corient IA LLC bought a new stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,000 shares of the medical equipment provider's stock, valued at approximately $284,000.
Several other institutional investors also recently bought and sold shares of the stock. Bessemer Group Inc. raised its position in Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock valued at $49,000 after purchasing an additional 1,701 shares during the last quarter. Sequoia Financial Advisors LLC bought a new position in Smith & Nephew SNATS during the 1st quarter valued at approximately $211,000. GAMMA Investing LLC raised its position in Smith & Nephew SNATS by 22.4% during the 1st quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock valued at $103,000 after purchasing an additional 666 shares during the last quarter. Townsquare Capital LLC raised its position in Smith & Nephew SNATS by 19.0% during the 4th quarter. Townsquare Capital LLC now owns 17,557 shares of the medical equipment provider's stock valued at $432,000 after purchasing an additional 2,798 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new position in Smith & Nephew SNATS during the 4th quarter valued at approximately $435,000. 25.64% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have commented on the company. Canaccord Genuity Group upped their price target on Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a research report on Thursday, May 1st. HSBC lowered Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, Hsbc Global Res lowered Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Six investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Smith & Nephew SNATS currently has a consensus rating of "Hold" and an average target price of $28.00.
Get Our Latest Stock Report on SNN
Smith & Nephew SNATS Stock Down 1.1%
Shares of NYSE:SNN opened at $36.20 on Monday. Smith & Nephew SNATS, Inc. has a 52-week low of $23.69 and a 52-week high of $36.84. The firm has a market capitalization of $15.85 billion, a P/E ratio of 16.76, a P/E/G ratio of 1.00 and a beta of 0.68. The stock has a 50 day moving average price of $31.24 and a 200-day moving average price of $28.87. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00.
Smith & Nephew SNATS Cuts Dividend
The company also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be given a $0.285 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a dividend yield of 210.0%. Smith & Nephew SNATS's dividend payout ratio is currently 41.20%.
About Smith & Nephew SNATS
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access